What Happened?
Shares of medical device company Artivion (NYSE: AORT) fell 26.8% in the afternoon session after it reported first-quarter results that missed Wall Street's profit expectations and lowered its full-year guidance for 2026.
The company’s adjusted earnings per share came in at $0.08, falling short of analysts' estimates of $0.12. While revenue of $116.3 million was in line with expectations, investors were discouraged by the company's revised outlook.
Artivion lowered its full-year revenue guidance to a midpoint of $488 million, down from $495 million previously. It also reduced its forecast for adjusted EBITDA, a measure of profitability, to a midpoint of $103.5 million. The combination of a quarterly earnings miss and a reduced financial forecast for the remainder of the year prompted a significant sell-off.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Artivion? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Artivion’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. Moves this big are rare for Artivion and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 9 months ago when the stock gained 20.3% on the news that it reported strong second-quarter 2025 earnings that surpassed analyst expectations and raised its full-year guidance.
The company's revenue for the quarter grew 15.3% year-over-year to $113 million, beating Wall Street's estimates. Its non-GAAP profit of $0.24 per share was also 92% above consensus forecasts, showcasing significant bottom-line strength.
Buoyed by the strong performance, Artivion lifted its full-year revenue guidance to a midpoint of $439 million. The results also revealed a marked improvement in cash generation, as its free cash flow margin expanded to 10.4%, up from 3.7% in the same quarter last year. This comprehensive beat and positive outlook fueled investor optimism, leading to the stock's jump.
Artivion is down 41.2% since the beginning of the year, and at $26.15 per share, it is trading 45.1% below its 52-week high of $47.63 from November 2025. Investors who bought $1,000 worth of Artivion’s shares 5 years ago would now be looking at only $886.27.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
